Shanghai - Delayed Quote CNY

Nanjing Vazyme Biotech Co., Ltd (688105.SS)

22.03
-0.28
(-1.26%)
At close: June 6 at 3:00:02 PM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
1,361,307.94
1,377,898.26
1,285,988.24
3,568,984.52
1,868,627.29
Cost of Revenue
414,291.11
414,356.56
372,563.16
1,110,510.96
350,847.71
Gross Profit
947,016.83
963,541.70
913,425.08
2,458,473.56
1,517,779.59
Operating Expense
1,008,896.84
1,019,096.60
951,704.61
1,221,502.74
721,364.52
Operating Income
-61,880
-55,554.89
-38,279.53
1,236,970.81
796,415.07
Net Non Operating Interest Income Expense
-11,531.34
-10,072.82
16,151.92
9,957.83
-789.01
Pretax Income
-60,157.54
-58,251.33
-115,714.26
609,389.80
764,445.02
Tax Provision
-37,516.03
-38,628.52
-42,852.29
15,882.94
86,155.45
Net Income Common Stockholders
-21,400.27
-18,093.81
-70,956.24
594,245.54
678,289.57
Basic EPS
-0.06
--
-0.18
1.49
1.87
Diluted EPS
-0.06
--
-0.18
1.49
1.87
Basic Average Shares
326,962.54
--
394,201.33
398,822.51
362,721.70
Diluted Average Shares
326,962.54
--
394,201.33
398,822.51
362,721.70
Total Operating Income as Reported
-60,934
-61,393.03
-100,180.24
717,493.85
771,138.25
Rent Expense Supplemental
--
24,622.33
38,274.22
32,129.08
10,019.99
Total Expenses
1,423,187.94
1,433,453.16
1,324,267.77
2,332,013.70
1,072,212.22
Net Income from Continuing & Discontinued Operation
-21,400.27
-18,093.81
-70,956.24
594,245.54
678,289.57
Normalized Income
-27,024.62
-19,355.37
-14,843.66
1,155,817.67
719,237.14
Interest Income
9,627.76
18,188.25
52,358.19
23,291.01
3,170.48
Interest Expense
25,282.75
27,254.98
35,065.83
12,475.36
3,863.55
Net Interest Income
-11,531.34
-10,072.82
16,151.92
9,957.83
-789.01
EBIT
-34,874.79
-30,996.35
-80,648.43
621,865.16
768,308.57
EBITDA
-34,874.79
121,513.49
76,728.22
743,964.61
823,585.65
Reconciled Cost of Revenue
414,291.11
414,356.56
372,563.16
1,110,510.96
350,847.71
Reconciled Depreciation
--
152,509.84
157,376.65
122,099.45
55,277.09
Net Income from Continuing Operation Net Minority Interest
-21,400.27
-18,093.81
-70,956.24
594,245.54
678,289.57
Total Unusual Items Excluding Goodwill
9,373.92
1,682.08
-89,114.06
-576,600.46
-46,148.68
Total Unusual Items
9,373.92
1,682.08
-89,114.06
-576,600.46
-46,148.68
Normalized EBITDA
-44,248.71
119,831.41
165,842.28
1,320,565.07
869,734.34
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
3,749.57
420.52
-33,001.48
-15,028.33
-5,201.11
12/31/2021 - 11/15/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

600161.SS TIANTAN BIO
20.15
+4.73%
 
688331.SS RemeGen Co., Ltd.
61.00
-0.81%
 
688578.SS Shanghai Allist Pharmaceuticals Co., Ltd.
94.30
-0.19%
 
688278.SS Xiamen Amoytop Biotech Co., Ltd.
73.64
-1.27%
 
688428.SS InnoCare Pharma Limited
24.56
+2.42%
 
138610.KQ NIBEC Co., Ltd.
27,200.00
-10.82%
 
688382.SS InventisBio Co., Limited
30.06
-0.03%
 
688180.SS Shanghai Junshi Biosciences Co., Ltd.
33.09
-1.93%
 
GYRE Gyre Therapeutics, Inc.
8.41
+5.52%
 
6875.TWO Pharmosa Biopharm Inc.
46.00
+0.88%